Peptide Protocol
Peptide Protocol
 App Store

TB-500: the complete guide

TB-500 is a synthetic peptide fragment based on the active region of thymosin beta-4, a naturally occurring protein involved in cell migration, angiogenesis, and wound healing.

Written by Peptide Protocol Editorial Medically reviewed per our review process Last reviewed
ClassSynthetic peptide fragment of thymosin beta-4
Half-lifeApproximately 2 hours (peptide); biological effect lasts longer
Typical dose2–5 mg (2000–5000 mcg) per injection, 1–2x weekly loading, then maintenance
CategoryHealing / tissue repair
Research useMuscle strains, tendon injuries, systemic healing research
FDA statusNot FDA approved. Research use only in the US.

How TB-500 works

TB-500 binds to G-actin and promotes cellular migration to sites of injury. It upregulates VEGF and stimulates new blood-vessel formation, which researchers link to faster tissue repair in animal models.

Typical TB-500 dosage

Commonly reported research ranges: 2–5 mg (2000–5000 mcg) per injection, 1–2x weekly loading, then maintenance.

Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.

How to reconstitute TB-500

A widely used reconstitution for a 10 mg vial is 3 ml of bacteriostatic water. With a typical 2000 mcg dose this works out to the unit count shown in the calculator below.

Open the TB-500 reconstitution calculator →

Pre-filled with the common 10 mg + 3 ml ratio. Adjust for your own vial.

Half-life and administration frequency

Approximately 2 hours (peptide); biological effect lasts longer.

This half-life informs how often TB-500 is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.

Reported side effects

This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.

Common TB-500 stacks

Full editorial stack guides featuring TB-500:

BPC-157 + TB-500

Tendon strains, post-surgical recovery, joint pain, slow-to-heal soft-tissue injuries.

HealingSoft tissue

Storage and handling

Lyophilized stable at room temp. Reconstituted: refrigerated, use within 28 days.

FDA and regulatory status

Not FDA approved. Research use only in the US.

TB-500 clinical trials and evidence

For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.

Track your TB-500 protocol on iPhone

Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.

See the app →

Frequently asked questions

What is TB-500?

TB-500 is a synthetic peptide fragment based on the active region of thymosin beta-4, a naturally occurring protein involved in cell migration, angiogenesis, and wound healing.

How does TB-500 work?

TB-500 binds to G-actin and promotes cellular migration to sites of injury. It upregulates VEGF and stimulates new blood-vessel formation, which researchers link to faster tissue repair in animal models.

What is a typical TB-500 dose?

Commonly reported ranges are 2–5 mg (2000–5000 mcg) per injection, 1–2x weekly loading, then maintenance. This is research information, not a recommendation — dosing should be individualized under clinical guidance.

What is the half-life of TB-500?

Approximately 2 hours (peptide); biological effect lasts longer. This influences how often it is administered.

How do you reconstitute TB-500?

A common approach is to add 3 ml of bacteriostatic water to a 10 mg vial. Use the reconstitution calculator for exact unit counts.

What are the side effects of TB-500?

Injection-site reactions; Temporary fatigue or head pressure (reported anecdotally); Limited long-term human safety data.

Is TB-500 FDA approved?

Not FDA approved. Research use only in the US.

Are there clinical trials for TB-500?

Registered or published clinical-trial sources for TB-500 are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.

References

  1. Thymosin beta-4 literature (PubMed) — National Library of Medicine. Primary literature on TB-4 and its active fragments including TB-500
  2. Goldstein et al. — Thymosin β4: a multi-functional regenerative peptide — PubMed. Foundational review of TB-4 biology and therapeutic potential
  3. Thymosin beta-4 clinical trial records — ClinicalTrials.gov. Registered human studies referencing TB-4

Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.

Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.